A Phase 1/2 interventional study of Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs) and Control group in Pressure Injuries - Stage 3 and Pressure Injuries - Stage 4, sponsored by Liaocheng People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Liaocheng People's Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pressure Ulcer with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Pressure Ulcer · China.
Among the 14 studies in Pressure Ulcer with a site in China, this one is one of 3 that started in 2024, is the only one in phase 1/2, and was the 7th registered.
548 studies on the registry are indexed under Pressure Ulcer; 127 are open to participants now.
Browse Pressure Ulcer studies →7 of the 14 studies in Pressure Ulcer with a site in China are open now. Recruiting first, the newest first:
Xuanqi Yang · Sites in China
Ages 60+
The First Hospital of Jilin University · Sites in China
Ages 18+
Affiliated Hospital of Guangdong Medical University · Sites in China
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 61 Pressure Ulcer studies recruiting now, 45 (74%) set no upper age limit and 6 (10%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 40 is below the median of 70 across 405 interventional studies indexed under Pressure Ulcer.
Median enrollment 78 across the 9 interventional studies, 1,200 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Liaocheng People's Hospital is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Liaocheng People's Hospital has 1 study filed under Pressure Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Pressure Ulcer with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07791056General Hospital of Ningxia Medical UniversityEffect of Positioning Protocol on Skin Pressure Injury and Shoulder Traction Pain in Neurosurgical Patients | 2026-12-01 |
| NCT06954857Xuanqi YangThe Influence of Standardized Process Management of Laryngeal Mask Airway Placement Based on Pressure Monitoring on the Incidence of Adverse Reactions in Elderly Patients During the Perioperative Period | 2027-03-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Pressure Ulcer with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) combined with platelet-rich plasma (PRP) in stage 3 and 4 stress injury.
The 2019 edition of the International Guidelines for Clinical Prevention and Treatment of Stress Injury states that stress injury, as a globally prevalent health issue, significantly reduces the quality of life for patients and their families, increases economic burden, and leads to significant expenditure on medical resources. In recent years, the incidence and mortality rate of pressure injuries in hospitalized patients have been increasing year by year. Therefore, there is an urgent need to find a more effective treatment method for pressure injuries in clinical practice. Human umbilical cord mesenchymal stem cells (huMSCs) have immunomodulatory and anti-inflammatory effects. Platelet rich plasma (PRP) can also secrete various nutritional factors, which can effectively promote wound healing. Therefore, the combination of the two may be a more effective treatment method for pressure injuries. At present, there are few reports on the combination of PRP and huMSCs for the treatment of pressure injury. In this study, the investigators aim to evaluate the effectiveness and safety of PRP combined with huMSCs for stage 3 and 4 pressure injuries, In order to promote their clinical application.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inject 3ml PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm.
Biological: Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)
Standard therapy
Other: Control group
Drug pages: Platelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SolizmestrocelStudies of SolizmestrocelSolizmestrocel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm
Standard therapy for patients with stage 3 and 4 stress injury
Change From Baseline in Pressure Ulcer Scale for Healing (PUSH)
The scale includes three dimensions: wound area, exudate volume, and tissue type. The total score of the three dimensions was indicated the healing of pressure injury and ranged from 0 to 17 points, with 0 points indicating wound healing. The PUSH score decreased, indicating improvement. The total score increased, indicating deterioration. Multiple pressure injuries in the same patient were evaluated separately.
Time frame: Baseline,1,2,4 and 6 weeks
Change from baseline in Determination of growth factor content
Serum epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) were detected during treatment.
Time frame: Baseline,1, 2 and 3 weeks
Wound healing time
The wound healing standard is wound closure and epithelial tissue coverage, and the wound healing time refers to the time from the date of direct treatment to wound healing for the patient. The wound healing time was recorded through dressing change in outpatient department or phone call follow-up.
Time frame: up to 4 months
Positive rate of bacterial culture
The patient's wound secretions were collected for bacterial culture on the day of stem cell treatment and 2 weeks after treatment.
Time frame: Baseline and 2 weeks
Safety evaluation
Any adverse events that occur during the treatment process must be recorded in detail. The record of adverse events should include a description of the adverse event and all related symptoms, the time of occurrence, severity, duration, measures taken, and the final outcome and outcome, as well as an evaluation of the possible correlation between the adverse event and treatment.
Time frame: up to 1 week
Plan to share: No
Start is estimated for Feb 2024; primary completion for Nov 2024, 8 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Platelet rich plasma · Solizmestrocel
Liaocheng People's Hospital